Evidence map›Paper›PMID 37945977›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension.

Omnia Azmy Nabeh, Alaa I Saud, Basma Amin, Amira Samy Khedr, Alaa Amr, Aml Medhat Faoosa, Eshraka Esmat, Yasmeen Magdy Mahmoud, Aya Hatem, Mariam Mohamed and 4 more

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Novel Therapies for Right Ventricular Failure.Current cardiology reports · 2025
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Omnia Azmy NabehMedical Pharmacology, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt. omnia.azmy@kasralainy.edu.eg.ORCID http://orcid.org/0000-0001-7959-9316
Alaa I SaudKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Basma AminKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Amira Samy KhedrKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Alaa AmrKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Aml Medhat FaoosaKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Eshraka EsmatKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Yasmeen Magdy MahmoudKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Aya HatemKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Mariam MohamedKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Alaa OsamaKasralainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Youssef Mohamed Amin SolimanPulmonology, Pulmonary Medicine Department, Kasr Alainy Hospital, Cairo University, Cairo, Egypt.
Reem Ibrahim ElkorashyPulmonology, Pulmonary Medicine Department, Kasr Alainy Hospital, Cairo University, Cairo, Egypt.
Soha Aly ElmorsyMedical Pharmacology, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary arterial hypertension (PAH) is a progressive, cureless disease, characterized by increased pulmonary vascular resistance and remodeling, with subsequent ventricular dilatation and failure. New therapeutic targets are being investigated for their potential roles in improving PAH patients' symptoms and reversing pulmonary vascular pathology.

methodWe aimed to address the available knowledge from the published randomized controlled trials (RCTs) regarding the role of Rho-kinase (ROCK) inhibitors, bone morphogenetic protein 2 (BMP2) inhibitors, estrogen inhibitors, and AMP-activated protein kinase (AMPK) activators on the PAH evaluation parameters. This systematic review (SR) was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CDR42022340658) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

resultsOverall, 5092 records were screened from different database and registries; 8 RCTs that met our inclusion criteria were included. The marked difference in the study designs and the variability of the selected outcome measurement tools among the studies made performing a meta-analysis impossible. However, the main findings of this SR relate to the powerful potential of the AMPK activator and the imminent antidiabetic drug metformin, and the BMP2 inhibitor sotatercept as promising PAH-modifying therapies. There is a need for long-term studies to evaluate the effect of the ROCK inhibitor fasudil and the estrogen aromatase inhibitor anastrozole in PAH patients. The role of tacrolimus in PAH is questionable. The discrepancy in the hemodynamic and clinical parameters necessitates defining cut values to predict improvement. The differences in the PAH etiologies render the judgment of the therapeutic potential of the tested drugs challenging.

conclusionMetformin and sotatercept appear as promising therapeutic drugs for PAH. CLINICAL TRIALS REGISTRATION: This work was registered in PROSPERO (CDR42022340658).

Indexed as

Hypertension, PulmonaryMetforminPulmonary Arterial HypertensionAMP-Activated Protein KinasesEstrogensFamilial Primary Pulmonary HypertensionHumansAMP-Activated Protein KinasesEstrogensMetformin

Identifiers

PMID37945977
PMCPMC10805839
OpenAlexW4388541033

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.